Barton Brezina, Wajeh Y. Qunibi, Charles R. Nolan  Kidney International 

Slides:



Advertisements
Similar presentations
Acid-Base Imbalance NRS What is pH? pH is the concentration of hydrogen (H+) ions The pH of blood indicates the net result of normal acid-base.
Advertisements

Volume 68, Pages S24-S28 (July 2005)
Acid-Base Imbalance.
Acid-base profile in patients on PD
Acid-Base Imbalance.
Volume 79, Pages S3-S8 (April 2011)
RenaGel®, a nonabsorbed calcium- and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone  Eduardo A. Slatopolsky, Steven K.
Pleiotropic effects of the non-calcium phosphate binder sevelamer
Acid-Base Imbalance.
Acid-Base Imbalance.
HYPERPHOSPHAT EMIA Group 5. Outlines -Disease manifestation (symptoms,signs), pathogenesis and pathophysiology. -Plan of treatment -Brief detail on pharmacology.
Volume 73, Issue 1, Pages 3-5 (January 2008)
Buffer transport in peritoneal dialysis
Acid-base profile in patients on PD
Sodium thiosulfate prevents vascular calcifications in uremic rats
Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients  G.A. Block, P. Raggi, A. Bellasi, L. Kooienga,
RenaGel®, a nonabsorbed calcium- and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone  Eduardo A. Slatopolsky, Steven K.
Calcium balance in normal individuals and in patients with chronic kidney disease on low- and high-calcium diets  David M. Spiegel, Kate Brady  Kidney.
Dieter A. Häberle, Wolfgang Biller, Takuyuki Ise, Christian J. Metz 
C-reactive protein and dialysis access
Volume 79, Pages S3-S8 (April 2011)
Differential effects of 19-nor-1,25-(OH)2D2 and 1α-hydroxyvitamin D2 on calcium and phosphorus in normal and uremic rats  Eduardo Slatopolsky, Mario Cozzolino,
Volume 65, Issue 5, Pages (May 2004)
Volume 55, Issue 1, Pages (January 1999)
Effect of acidosis on urine supersaturation and stone formation in genetic hypercalciuric stone-forming rats  David A. Bushinsky, Marc D. Grynpas, John.
Volume 76, Pages S50-S99 (August 2009)
High volume peritoneal dialysis vs daily hemodialysis: A randomized, controlled trial in patients with acute kidney injury  D.P. Gabriel, J.T. Caramori,
James F. List, Jean M. Whaley  Kidney International 
Treatment of hyperphosphatemia in patients with chronic kidney disease on maintenance hemodialysis: Results of the CARE study  Wajeh Y. Qunibi, Charles.
Volume 68, Pages S7-S14 (July 2005)
D. Batlle, P. Ramadugu, M.J. Soler  Kidney International 
A new era in phosphate binder therapy: What are the options?
Pleiotropic effects of the non-calcium phosphate binder sevelamer
Darbepoetin alfa: A new therapeutic agent for renal anemia
Comparative effects of potassium chloride and bicarbonate on thiazide-induced reduction in urinary calcium excretion  Lynda A. Frassetto, Eileen Nash,
American Journal of Kidney Diseases
Volume 66, Pages S25-S32 (September 2004)
Correction to "Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate.
Charles R. Nolan, Wajeh Y. Qunibi  Kidney International 
Volume 69, Issue 3, Pages (February 2006)
Volume 68, Pages S24-S28 (July 2005)
Effect of bolus and divided feeding on urine ions and supersaturation in genetic hypercalciuric stone-forming rats  D.A. Bushinsky, A.C. Michalenka, K.L.
Volume 63, Issue 1, Pages (January 2003)
Joel D. Kopple, Kamyar Kalantar-Zadeh, Rajnish Mehrotra 
Role of vitamin D receptor activators on cardiovascular risk
Volume 56, Pages S31-S37 (December 1999)
Volume 60, Issue 1, Pages (July 2001)
The role of daily dialysis in the control of hyperphosphatemia
It Is Really Time for Ammonium Measurement
Rajnish Mehrotra, Joel D. Kopple, Marsha Wolfson  Kidney International 
Treatment of hyperphosphatemia with sevelamer hydrochloride in dialysis patients: effects on vascular calcification, bone and a close look into the survival.
Volume 74, Issue 4, Pages (August 2008)
Yasunori Kitamoto, Katsuhiko Matsuo, Kimio Tomita  Kidney International 
Volume 68, Issue 1, Pages (July 2005)
Phosphate binders on iron basis: A new perspective?
Quiz page answers June 2005 American Journal of Kidney Diseases
Total hip bone mass predicts survival in chronic hemodialysis patients
Jacob Lemann, Nancy D. Adams, Donald R. Wilz, Luis G. Brenes 
Role of sodium in hemodialysis
Calcium phosphate supersaturation regulates stone formation in genetic hypercalciuric stone-forming rats  David A. Bushinsky, M.D., Walter R. Parker,
Charles A. Herzog  Kidney International 
Quiz Page June 2011 American Journal of Kidney Diseases
Volume 62, Issue 5, (November 2002)
Chronic metabolic acidosis in azotemic rats on a high-phosphate diet halts the progression of renal disease  Aquiles Jara, Arnold J. Felsenfeld, Jordi.
Strategies for iron supplementation: Oral versus intravenous
Evaluation of the Losartan in Hemodialysis (ELHE) Study
Control of uremic bone disease: Role of vitamin D analogs
Metabolic Acidosis in CKD: Core Curriculum 2019
Volume 82, Issue 11, Pages (December 2012)
Takuyuki Ise, Ken-ichi Kobayashi, Wolfgang Biller, Dieter A. Häberle 
Presentation transcript:

Acid loading during treatment with sevelamer hydrochloride: Mechanisms and clinical implications  Barton Brezina, Wajeh Y. Qunibi, Charles R. Nolan  Kidney International  Volume 66, Pages S39-S45 (September 2004) DOI: 10.1111/j.1523-1755.2004.09007.x Copyright © 2004 International Society of Nephrology Terms and Conditions

Figure 1 Serum bicarbonate levels during treatment with calcium acetate or sevelamer hydrochloride in the CARE study. Mean serum bicarbonate levels at baseline and weekly during treatment in patients randomized to treatment with either calcium acetate (○) or sevelamer hydrochloride (♦). At baseline, serum bicarbonate was not significantly different between the calcium acetate and sevelamer hydrochloride groups (P value 0.11). However, during treatment mean serum bicarbonate levels were significantly lower in the sevelamer group than in the calcium acetate group (P value < 0.0001 by covariate-adjusted repeated measures regression) (A). Observed and model-estimated percent of subjects with serum bicarbonate <22 mEq/L by treatment group and week. Main treatment effect: P value < 0.0001. Reprinted with permission from Qunibi WY, Hootkins RE, McDowell LL, et al: Treatment of hyperphosphatemia in hemodialysis patients: The calcium acetate Renagel evaluation (CARE study). Kidney Int 65:1914–1926, 2004 (B). Kidney International 2004 66, S39-S45DOI: (10.1111/j.1523-1755.2004.09007.x) Copyright © 2004 International Society of Nephrology Terms and Conditions

Figure 2 Theoretical mechanisms of acid loading during treatment with sevelamer hydrochloride. Monovalent phosphate is bound to the sevelamer polymer via ionic and hydrogen-bonding interactions in exchange for release of the leaving anion chloride. For each phosphate molecule bound, one molecule of hydrochloride is produced (A). Exchange of chloride for bicarbonate in the small intestine. Loss of carbonated sevelamer in the stool leads to gastrointestinal losses of bicarbonate in excess of chloride. The net effect is production of excess HCl acid resulting in metabolic acidosis by a mechanism akin to development of nonanion gap metabolic acidosis in the setting of diarrhea (B). Sequestration of bile acids (cholic acid and chenodeoxycholic acid) by sevelamer in exchange for release of chloride. The net effect is the production of one HCl molecule for every molecule of bile acid bound (C). CA, carbonic anhydrase; GI, gastrointestinal. Kidney International 2004 66, S39-S45DOI: (10.1111/j.1523-1755.2004.09007.x) Copyright © 2004 International Society of Nephrology Terms and Conditions

Figure 3 Rat model demonstrating increased urinary net acid excretion during treatment with sevelamer hydrochloride. Normal rats (N = 18, 250 g male Sprague-Dawley) were placed on a regular diet for six days and then divided into three groups of six rats and treated with test agents admixed with diet for seven days as follows: group 1, sevelamer hydrochloride: 1 g/day containing 5 mmol/L chloride (closed squares); group 2, HCl acid: 5 mmol/day (open squares); and group 3, sodium chloride: 5 mmol/day (open circles). Rats were housed in metabolic cages to measure 24-hour urine for pH (A) and NH4+ excretion (μmol/day; measured by ion specific electrode) (B). *P < 0.05 vs. baseline and other treatment groups, †P < 0.05 vs. baseline and NaCl treatment group, §P < 0.05 vs. baseline and HCl acid treatment groups. Kidney International 2004 66, S39-S45DOI: (10.1111/j.1523-1755.2004.09007.x) Copyright © 2004 International Society of Nephrology Terms and Conditions

Figure 4 Effects of metabolic acidosis on protein metabolism. Kidney International 2004 66, S39-S45DOI: (10.1111/j.1523-1755.2004.09007.x) Copyright © 2004 International Society of Nephrology Terms and Conditions

Figure 5 Effects of metabolic acidosis on bone disease. Kidney International 2004 66, S39-S45DOI: (10.1111/j.1523-1755.2004.09007.x) Copyright © 2004 International Society of Nephrology Terms and Conditions